Skip to Main Content

Biotech executives and a handful of academics pleaded with U.S. and European regulators on Thursday to adopt new standards for approving antibody drugs against Covid, particularly for immunocompromised and other vulnerable patients.

The four-hour hearing came as agencies, companies, and researchers face a fundamental mismatch: The virus is evolving faster than our ability to develop interventions under normal — or even normal emergency — procedures.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment